Literature DB >> 30906765

Central nervous system activity of first-line osimertinib in epidermal growth factor receptor-mutant advanced non-small cell lung cancer.

Chong-Kin Liam1.   

Abstract

Entities:  

Year:  2019        PMID： 30906765      PMCID： PMC6389567          DOI： 10.21037/atm.2018.12.68

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  4 in total

1.  ADAURA: Mature Enough for Publication, Not for Prime Time.

Authors:  Alfredo Addeo; Giuseppe Luigi Banna; Alex Friedlaender
Journal:  Oncologist       Date:  2020-12-24

2.  Circulating tumor DNA clearance predicts prognosis across treatment regimen in a large real-world longitudinally monitored advanced non-small cell lung cancer cohort.

Authors:  Yong Song; Chengping Hu; Zhanhong Xie; Lin Wu; Zhengfei Zhu; Chuangzhou Rao; Li Liu; Yuan Chen; Naixin Liang; Jun Chen; Chunhong Hu; Nong Yang; Jie Hu; Weixin Zhao; Gangling Tong; Xiaorong Dong; Di Zheng; Meiling Jin; Jianhua Chen; Meijuan Huang; Yong He; Rafael Rosell; Giuseppe Lippi; Mari Mino-Kenudson; Han Han-Zhang; Xinru Mao; Lu Zhang; Hao Liu; John K Field; Shannon Chuai; Junyi Ye; Yusheng Han; Shun Lu
Journal:  Transl Lung Cancer Res       Date:  2020-04

Review 3.  Ablative Radiotherapy as a Strategy to Overcome TKI Resistance in EGFR-Mutated NSCLC.

Authors:  Jennifer Novak; Ravi Salgia; Howard West; Miguel A Villalona-Calero; Sagus Sampath; Terence Williams; Victoria Villaflor; Erminia Massarelli; Ranjan Pathak; Marianna Koczywas; Brittney Chau; Arya Amini
Journal:  Cancers (Basel)       Date:  2022-08-18       Impact factor: 6.575

4.  Comparative Efficacy of Systemic Agents for Brain Metastases From Non-Small-Cell Lung Cancer With an EGFR Mutation/ALK Rearrangement: A Systematic Review and Network Meta-Analysis.

Authors:  Shervin Taslimi; Karanbir Brar; Yosef Ellenbogen; Jiawen Deng; Winston Hou; Fabio Y Moraes; Michael Glantz; Brad E Zacharia; Aaron Tan; Manmeet S Ahluwalia; Mustafa Khasraw; Gelareh Zadeh; Alireza Mansouri
Journal:  Front Oncol       Date:  2021-12-07       Impact factor: 6.244
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.